TY  - JOUR
AU  - Bishton, Mark
AU  - Marshall, Scott
AU  - Harchowal, Jatinder
AU  - Salles, Gilles
AU  - Golfier, Camille
AU  - Tucci, Alessandra
AU  - Fernández, Alicia Rodriguez
AU  - Sanchez Blanco, Jose Javier
AU  - Bocchia, Monica
AU  - Kim, SooKyoung
AU  - Lee, Young Nam
AU  - Zinzani, Pier Luigi
PY  - 2022
DO  - 10.1002/hon.2978
UR  - http://hdl.handle.net/10668/22028
T2  - Hematological oncology
AB  - Rapid infusion (RI) of the rituximab biosimilar CT-P10 is currently only an approved treatment regimen for the treatment of rheumatoid arthritis. Although both CT-P10 and reference rituximab are known to be frequently administered using a RI regimen...
LA  - en
KW  - biosimilar pharmaceuticals
KW  - chronic
KW  - infusion
KW  - intravenous
KW  - lymphocytic leukemia
KW  - lymphoma
KW  - non-Hodgkin
KW  - rituximab
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - Biosimilar Pharmaceuticals
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - Lymphoma, Non-Hodgkin
KW  - Retrospective Studies
KW  - Rituximab
KW  - Treatment Outcome
TI  - The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
TY  - research article
VL  - 40
ER  -